Introduction: To evaluate graft- and patient survival after paediatric kidney transplantation and detecting influence factors, which affect the post-transplant time. Materials and Methods: We analysed long-term survival rates and complications after paediatric kidney transplantation and searched for predictive parameters for graft function. Results: In 132 patients, 143 kidney transplantations were performed. Graft failure occurred in 25%. Chronic rejections were the leading cause of graft loss (42.9%). Graft survival rates were 92.2% after 1 year, 85.5% after 5 years, 71.1% after 10 years and 62.1% after 15 years. The following parameters strongly influenced graft survival: number of transplants (p = 0.014), year of transplant (p < 0.0001 for 1997–2005), Epo-therapy post-transplant (p = 0.001), hypotension donor (p = 0.027), cold ischemia time (p = 0.023), anastomosis time >50 min (p = 0.008), delayed graft function (p = 0.003) and deceased donation (p = 0.039). The percentage of patients who died was 5.6%. Overall patient survival rates were 99.3% after 1 year, 95.2% after 5 years, 94.2% after 10 years and 90.7% after 15 years. Various types of infections (42.9%) were the main causes of death. Conclusions: The main causes of death after kidney transplantations in paediatric recipients are malignancy and infections. To avoid vascular complications especially in young recipients (<9 years), the cold ischemia time should be as short as possible.

Keywords:
Influence factors, Paediatric transplantation, Vascular complications
1.
McDonald SP, Craig JC: Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350: 2654–2662.
2.
Nissel R, Brázda I, Feneberg R, et al: Effect of renal transplantation in childhood on longitudinal growth and adult height. Kidney Int 2004; 66: 792–800.
3.
Goldstein SL, Graham N, Burwinkle T, et al: Health-related quality of life in pediatric patients with ESRD. Pediatr Nephrol 2006; 21: 846–850.
4.
Mehls O, Scharer K: Padiatrische Nephrologie. Berlin, Springer, 2002.
5.
Offner G: [Pediatric kidney transplantation]. Urologe A 2009; 48: 1464–1467.
6.
Smith JM, Martz K, Blydt-Hansen TD: Pediatric kidney transplant practice patterns and outcome benchmarks, 1987–2010: a report of the North American Pediatric Renal Trials and Collaborative Studies. Pediatric Transplant 2013; 17: 149–157.
7.
Smith JM, Fine RN, McDonald RA: Current state of pediatric renal transplantation. Front Biosci 2008; 13: 197–203.
8.
Tönshoff B, David-Neto E, Ettenger R, et al: Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant Rev (Orlando) 2011; 25: 78–89.
9.
Mitsnefes MM: Hypertension and end-organ damage in pediatric renal transplantation. Pediatric Transplant 2004; 8: 394–399.
10.
Seeman T: Hypertension after renal transplantation. Pediatric Nephrol 2007; 24: 959–972.
11.
Harambat J, Cochat P: Growth after renal transplantation. Pediatric Nephrol 2008; 24: 1297–1306.
12.
Vester U, Schaefer A, Kranz B, et al: Development of growth and body mass index after pediatric renal transplantation. Pediatric Transplant 2005; 9: 445–449.
13.
John U, Kemper MJ: Urinary tract infections in children after renal transplantation. Pediatric Nephrol 2008; 24: 1129–1136.
14.
Gillen DL, Stehman-Breen CO, Smith JM, et al: Survival advantage of pediatric recipients of a first kidney transplant among children awaiting kidney transplantation. Am J Transplant 2008; 8: 2600–2606.
15.
Gulati A, Sarwal MM: Pediatric renal transplantation: an overview and update. Curr Opin Pediatr 2010; 22: 189–196.
16.
Mehrabi A, Kashfi A, Tönshoff B, et al: Long-term results of paediatric kidney transplantation at the University of Heidelberg: a 35 year single-centre experience. Nephrol Dial Transplant 2004; 19(suppl 4):iv69–iv74.
17.
Oh J, Schaefer F, Veldmann A, et al: Heterozygous prothrombin gene mutation: a new risk factor for early renal allograft thrombosis. Transplantation 1999; 68: 575–578.
18.
Dharnidharka VR, Sullivan EK, Stablein DM, et al: North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Risk factors for post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71: 1065–1068.
19.
McDonald RA, Smith JM, Ho M, et al: Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibi-tor, sirolimus and steroids. Am J Transplant 2008; 8: 984–989.
20.
Cleper R, Ben Shalom E, Landau D, et al: Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients – a national study. Pediatr Transplant 2012; 16: 619–626.
21.
Dharnidharka VR, Talley LI, Martz KL, et al: Recombinant growth hormone use pretransplant and risk for post-transplant lymphoproliferative disease – a report of the NAPRTCS. Pediatr Transplant 2008; 12: 689–695.
22.
Uchida J, Iwai T, Kabei K, et al: AB0-incompatible living kidney transplant recipients from spousal donors receiving rituximab. Urol Int 2016; 97: 457–465.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.